



SKG
INVESTMENTS & ADVISORY

MONTHLY REPORT · IPO

Monthly IPO Coverage

May 2026

Published: June 2026

2026

Contents

01

AMBA Auto Sales and Services Ltd
/ NSE Emerge

02

Q-Line Biotech Limited
/ NSE Emerge

03

Recode Studios Limited
/ NSE Emerge

04

Simca Advertising Limited / NSE Emerge

05

Teamtech Formwork Solutions
/ NSE Emerge

06

Bio Medica Laboratories Limited
/ NSE Emerge

AMBA Auto Sales and Services Ltd

| NSE Emerge

Business Overview: Authorised dealer of Bajaj Auto (2W/3W) and LG Electronics in Bengaluru. Revenue spans new vehicle sales, after-sales service, spare parts, and insurance facilitation.



IPO Details

Particulars	Details
Issue Type	Fresh Issue Only – 100% Book Built
Issue Size	48,24,000 Shares – ₹ 65.12 Cr
Price Band	₹ 130 – ₹ 135 per share
Lot Size	Min 2,000 shares; multiples of 1,000
Market Cap	₹ 247.37 Cr (at ₹ 135)
Promoter Holding Pre-Post- IPO	96.67% → 71.22%
Lead Manager	Capital square Advisors



Post Fund Raise

Particulars	Pre-IPO	Post-IPO
Gross Proceeds	-	₹ 65.12 Cr
Total Debt (Lacs)	₹ 5,742	₹ 5,742
Total Equity (Lacs)	₹ 2,690	₹ 7,428
D/E Ratio (x)	2.13x	0.77x



Financial Summary (₹ Lakhs)

Metric	9M FY26	FY25	FY24	FY23
Revenue	20,374	24,237	21,123	11,295
EBITDA	2,234	1,748	841	445
EBITDA%	10.97%	7.21%	3.98%	3.94%
PAT	1,211	778	289	64
PAT%	5.94%	3.21%	1.37%	0.57%
Net Worth	2,690	1,514	737	448
ROAE	57.61%	69.09%	48.74%	15.04%
ROCE	26.82%	24.31%	18.14%	12.47%



Market Potential

Segment	Value	Note / CAGR
Auto Industry FY25E	₹ 11.1 Tn	CAGR 8.38% (FY25-30)
2W Segment FY25	+7.71%	Strong retail momentum
3W Market FY24	6.92 L units	CAGR 3% to FY33
Cons. Electronics	₹ 3.5 Tn FY24	CAGR 17.44% → ₹ 14.9 Tn FY33
LG Washing Machine	27.10% share	#1 brand in India



Risks & Opportunities

Key Risks



OEM dependence – Bajaj Auto & LG sole principals



Debt/Equity: 0.77x post issue vs industry avg 0.34x, Brought down to 2.13 in last 1 year from 3.65x



Geographic concentration – all revenues from Bengaluru / KA

Key Opportunities



Auto CAGR 8.38% (FY25-30); EV push via Chetak



Consumer electronics CAGR 17.44% through FY33



IPO-funded expansion: 7 new showrooms (3x2W + 4x3W)

Q-Line Biotech Limited

| NSE Emerge

Business Overview: Manufactures and markets in-vitro diagnostic (IVD) reagents, kits, and POC devices, and distributes imported diagnostic analysers to hospitals and labs. Operates 4 manufacturing/R&D facilities across UP and Delhi since 2013.



IPO Details

Particulars	Details
Issue Type	Fresh Issue Only - 100% Book Built
Fresh Issue	62,53,200 Shares - ₹214.48 Cr
Price Band	₹326 - ₹343 per share
Lot Size	400 Equity Shares
Market Cap	₹855 Cr (at ₹343)
Promoter Holding Pre→ Post- IPO	92.24% → 67.51%
Lead Manager	Hem Securities, Share India Capital Services



Post Fund Raise

Particulars	Pre-IPO	Post-IPO
Gross Proceeds	-	₹214.48 Cr
Total Debt (Lacs)	₹24,385.48	₹15,385.48
Total Equity (Lacs)	₹22,916.42	₹47,108.89
D/E Ratio (x)	1.06x	0.33x



Financial Summary (₹ Lakhs)

Metric	9M FY26	FY25	FY24	FY23
Revenue	23,242	31,378	20,365	18,274
EBITDA	6,423	7,132	3,763	3,298
EBITDA%	27.6%	22.7%	18.5%	18.1%
PAT	3,869	2,813	3,445	3,210
PAT%	16.7%	9.0%	16.9%	17.6%
Net Worth	22,916	18,995	16,181	12,737
ROE	16.9%	23.7%	21.3%	25.2%
ROCE	13.3%	17.7%	19.3%	22.1%



Market Potential

Segment	Value	Note
India IVD Market (CY25)	USD 2,000 Mn	CAGR 12.2% → USD 2,978 Mn CY30
Reagents & Kits	USD 1,318 Mn	66% share; recurring consumables
POCT Devices	Fast-growing	Expanding point-of-care diagnostics
Co. Revenue CAGR	31.04%	FY23-FY25; outpaces market
IVF/ART Products	New vertical	Entering reproductive health



Risks & Opportunities

Key Risks



Raw material supply risk - reliant on domestic & imported suppliers



Income Tax search & seizure on promoters and erstwhile associate



Geographic concentration - majority revenues from North India

Key Opportunities



IVD market CAGR 12.2% (CY25-30); diagnostics awareness driving growth



Reverse engineering of imported kits - import substitution potential



Pan-India distribution across 4 regions; expansion with IPO proceeds

Recode Studios Limited

| NSE Emerge

Business Overview: Branding, procurement, and distribution of cosmetics and personal care products under the 'Recode' brand. Asset-light model - no owned manufacturing; sells via COCO/FOFO stores, e-commerce, and its own app.



IPO Details

Particulars	Details
Issue Type	Fresh Issue + OFS - 100% Book Built
Fresh Issue	25,03,200 Shares - ₹39.55 Cr
OFS	3,19,200 Shares - ₹5.04 Cr
Price Band	₹150 - ₹158 per share
Lot Size	800 Equity Shares
Market Cap	₹447 Cr (at ₹158)
Promoter Holding Pre→Post-IPO	88.93% → 65.02%
Lead Manager	Seren Capital



Post Fund Raise

Particulars	Pre-IPO	Post-IPO
Gross Proceeds	-	₹44.59 Cr (Total Offer)
Total Debt (Lacs)	₹342.76	₹342.76
Total Equity (Lacs)	₹1,783.65	₹5738.71
D/E Ratio (x)	0.19x	0.06x



Financial Summary (₹ Lakhs)

Metric	9M FY26	FY25	FY24	FY23
Revenue	5,739	4,780	3,682	2,238
EBITDA	1,334	613	167	144
EBITDA%	23.2%	12.8%	4.5%	6.4%
PAT	906	330	27	69
PAT%	15.8%	6.9%	0.7%	3.1%
Net Worth	1,784	877	547	520
ROE	68.1%	46.4%	5.1%	24.6%
ROCE	59.9%	34.5%	9.4%	14.3%



Market Potential

Segment	Value	Note
India Outdoor Adv (OOH)	₹4,695 Cr (CY24)	CAGR 3.78% CY19-24; Digital OOH fast growing
Digital OOH (DOOH)	Rising share	Recode derives 38% revenue from DOOH (FY25)
India Total Ad Mkt	₹1,02,097 Cr	Growing to ₹1,83,005 Cr by CY31 at 8.7% CAGR
Revenue CAGR FY23-25	46.2%	Strong growth driven by DOOH expansion



Risks & Opportunities

Key Risks



Business concentrated in outdoor/hoarding advertising - technology disruption risk



Short operating history - incorporated 2021; limited track record



Regulatory risk - outdoor advertising regulations by municipal bodies

Key Opportunities



DOOH market growing at 15%+ CAGR; Recode early mover in Punjab/North India



Event sponsorships & campaigns - new revenue line growing rapidly



D2C brand advertisers increasingly allocating budgets to OOH for brand awareness

Simca Advertising Limited

| NSE Emerge

Business Overview: Mumbai-based Out-of-Home (OOH) advertising company offering hoardings, gantries, bus panels, shelters, and kiosks across Mumbai and Maharashtra. No long-term client contracts; operates on short-term purchase orders.



IPO Details

Particulars	Details
Issue Type	Fresh Issue Only – 100% Book Built
Fresh Issue	31,71,600 Shares – ₹58.04 Cr
Price Band	₹174 – ₹183 per share
Lot Size	1,200 Equity Shares
Market Cap	₹219 Cr (at ₹183)
Promoter Holding Pre→Post-IPO	99.99% → 73.50%
Lead Manager	Socradamus Capital



Post Fund Raise

Particulars	Pre-IPO	Post-IPO
Gross Proceeds	-	₹58.04 Cr
Total Debt (Lacs)	₹13.87	₹13.87
Total Equity (Lacs)	₹2,804.55	₹8,616.63
D/E Ratio (x)	0.0049x	0.0016x



Financial Summary (₹ Lakhs)

Metric	9M FY26	FY25	FY24	FY23
Revenue	7,778	7,494	4,931	1,196
EBITDA	1,437	1,349	772	211
EBITDA%	18.5%	18.0%	15.7%	17.7%
PAT	1,068	998	578	157
PAT%	13.7%	13.3%	11.7%	13.1%
Net Worth	2,805	1,737	739	162
ROE	38.1%	57.4%	78.1%	96.9%
ROCE	50.9%	76.6%	104.5%	127.5%



Market Potential

Segment	Value	Note
India OOH Ad Market	₹4,695 Cr (CY24)	CAGR 3.78% CY19-24; digital shift accelerating
DOOH Growth	Fast expanding	DOOH projected CAGR 15%+ driven by programmatic
India Ad Mkt Size	₹1,02,097 Cr	Growing to ₹1,83,005 Cr by CY31E at 8.7% CAGR
Revenue CAGR FY23-25	150%+	Rapid scale-up from ₹1,196 Cr to ₹7,494 Cr
Client Mix	Diversified	Brand clients across BFSI, FMCG, real estate, govt.



Risks & Opportunities

Key Risks



Very short operating history – incorporated March 2022; rapid scale-up creates risk



High trade receivable days (103-168 days) – working capital intensive



Revenue concentration – top clients likely significant share; churn risk

Key Opportunities



Digital Out-of-Home (DOOH) segment growing rapidly; Simca early mover in Mumbai/MH



Event sponsorships & campaigns: entirely new revenue vertical growing



India ad market projected at ₹1.83 Lakh Cr by CY31; structural growth underpins business

Teamtech Formwork Solutions

| NSE Emerge

Business Overview: B2B manufacturer, refurbisher, and rental provider of modular T-formwork systems for vertical concrete construction. Serves infrastructure and real estate contractors; also offers a capex-free rental model.



IPO Details

Particulars	Details
Issue Type	Fresh Issue Only – 100% Book Built
Fresh Issue	79,60,000 Shares – ₹50.15 Cr
Price Band	₹61 – ₹63 per share
Lot Size	2,000 Equity Shares
Market Cap	₹794 Cr (at ₹63)
Promoter Holding Pre→Post-IPO	81.25% → 59.67%
Lead Manager	Getfive Advisors



Post Fund Raise

Particulars	Pre-IPO	Post-IPO
Gross Proceeds	-	₹50.15 Cr
Total Debt (Lacs)	₹1,667.56	₹1,667.56
Total Equity (Lacs)	₹3,321.97	₹8,336.77
D/E Ratio (x)	0.50x	0.09x



Financial Summary (₹ Lakhs)

Metric	FY25	FY24	FY23
Revenue	5,366	3,271	3,030
EBITDA	1,750	924	911
EBITDA%	32.6%	28.3%	30.1%
PAT	1,159	784	769
PAT%	21.6%	24.0%	25.4%
Net Worth	3,322	2,163	1,379
ROE	42.3%	44.3%	76.4%
ROCE	40.9%	37.5%	57.4%



Market Potential

Segment	Value	Note
India Formwork Mkt	₹5,000+ Cr	Growing with infra & real estate boom
Construction CAGR	~10-12% p.a.	Govt capex + housing push driving demand
Revenue CAGR FY24-26	33% (2-year)	Company growing faster than sector
Operating Margin	32.6% EBITDA	Rental model drives high margins
Formwork Rental	Asset-light mod	Recurring revenue from rentals



Risks & Opportunities

Key Risks



Revenue concentrated in EPC segment; customer concentration from top 10 clients



Working capital intensive; extended credit to large contractors may strain cash flows



Competition from Chinese imported formwork systems and unorganised domestic players

Key Opportunities



India's infra boom: NIP ₹111 Lakh Cr & PMAY housing target drives formwork demand



FY26 revenue ₹53.66 Cr (64% growth) – strong execution momentum validates model



Expanding into new geographies; high-margin rental business scales with asset base

Bio Medica Laboratories Limited

| NSE Emerge

Business Overview: Contract manufacturer of pharmaceutical parenteral formulations (liquid and dry powder injectables) for human and veterinary use. Pure B2B, no direct retail; GMP and GLP certified, operating out of Indore.



IPO Details

Particulars	Details
Issue Type	Fresh Issue + OFS – 100% Book Built
Fresh Issue	33,95,000 Shares – ₹47.19 Cr
OFS	3,77,000 Shares – ₹5.24 Cr
Price	₹132 – ₹139 per share
Lot Size	1,000 Equity Shares
Market Cap	₹194 Cr (at ₹139)
Promoter Holding Pre→ Post- IPO	96.84% → 67.69%
Lead Manager	Narnolia Financial Services



Post Fund Raise

Particulars	Pre-IPO	Post-IPO
Gross Proceeds	-	₹47.19 Cr (Fresh)
Total Debt (Lacs)	₹3,816.82	₹3,166.82
Total Equity (Lacs)	₹1,711.61	₹6,430.66
D/E Ratio (x)	2.23x	0.49x (est.)



Financial Summary (₹ Lakhs)

Metric	8M FY26	FY25	FY24	FY23
Revenue	2,855	3,820	1,525	1,623
EBITDA	1,345	1,521	563	170
EBITDA%	47.1%	39.8%	36.9%	10.5%
PAT	866	979	250	33
PAT%	30.4%	25.6%	16.4%	2.1%
Net Worth	1,712	1,473	494	244
ROE	54.4%	99.6%	67.7%	13.9%
ROCE	23.24%	48.20%	29.92%	10.16%



Market Potential

Segment	Value	Note
India API Market	USD 4 Bn (2024)	India is global API hub; China+1 drives exports
Pharma CAGR	~10% p.a.	USD 15 Bn pharma mkt growing on generics
Nutraceuticals	₹50,000 Cr mkt	Post-COVID wellness surge drives nutra demand
Revenue CAGR FY23-25	53.5%	Rapid capacity expansion at Indore facility
EBITDA Expansion	10% → 40%+	Shift to value-added formulations & APIs



Risks & Opportunities

Key Risks	Key Opportunities
Negative operating cash flow in FY25 (–₹367L) and 8M FY26 (–₹576L) – working capital risk	EBITDA expansion from 10% (FY23) to 47% (8M FY26) signals strong product mix improvement
Top 2 customers share in Revenue is greater than 50%.	WHO–GMP certified plant + DSIR–recognised R&D positions for export market entry
API/pharma industry subject to USFDA, EU GMP, CDSCO approvals– regulatory risk	Nutraceuticals growth wave: post-COVID wellness awareness drives premium supplement demand

Disclaimer

The above material is neither investment research, nor investment advice. SKG - Investments & Advisory ("SKG") does not seek payment for or business from this material/email in any shape or form. No content of this publication including the performance related information is verified by SEBI. If any recipient or reader of this material is based outside India, please note that SKG may not be regulated in such jurisdiction and this material is not a solicitation to use SKG's services. The recipient of this material is urged to consult their own legal and tax consultants/advisors before making any investments. The recipient, if not the addressee, should not use this material if erroneously received, and access and use of this material in any manner by anyone other than the addressee is unauthorized. If you are not the intended recipient, please notify the sender by return email and immediately destroy all copies of this message and any attachments and delete it from your computer system, permanently. No liability whatsoever is assumed by SKG as a result of the recipient or any other person relying upon the opinion unless otherwise agreed in writing. The recipient acknowledges that SKG may be unable to exercise control or ensure or guarantee the integrity of the text of the material/email message and the text is not warranted as to its completeness and accuracy. The material, names and branding of the investment style do not provide any impression or a claim that these products/strategies achieve the respective objectives. Further, past performance is not indicative of future results. SKG and/or its associates, the authors of this material (including their relatives) may have financial interest by way of investments in the companies covered in this material. SKG does not receive compensation from the companies for their coverage in this material. SKG does not provide any market making service to any company covered in this material. Authors of this material have never served the companies in a capacity of a director, officer or an employee. All recipients of this material must before dealing and or transacting in any of the products referred to in this material must make their own investigation, seek appropriate professional advice and carefully read the Private Placement Memorandum/Disclosure Document, Form ADV, Form CRS and any other documents or disclosures provided to them by SKG, as applicable.



SKG
INVESTMENTS & ADVISORY



20 *years of
financial excellence*

THE SKG GROUP

SKG Assets & Holding Pvt Ltd
SKG Asset Management Pvt Ltd
Equity first LLP
Madhuri Holding Ltd